Biomedical subjects
Publications and source records attributed to A E Rudenko.
A positive result has been obtained in treating sleep disorders in patients with chronic vascular affections of the brain with using the drugs donormyl and sonnate-KM [symbol: see text]. Donormyl is recommended for use in sleep disturbances (not very prolonged and not profound insomnia) in a 10-day therapeutic course as a first-choice drug.
The author present comparative analysis of rheoencephalographic (REG) data obtained from 500 differently aged Kiev residents with atherosclerotic dyscirculatory encephalopathy after Chernobyl accident. Changes of principal REG parameters are determined as the plethoric syndrome (PS). Main variants of nerves characterizing PS are divided into three types. Data obtained by the authors confirmed changes of the vascular system under the new ecological conditions.
The frequency and severity of residual phenomena after viral meningoencephalitis is to large degree determined by the premorbid background, etiology, severity of the acute period of the disease hospitalization terms. Among the residual phenomena functional disorders are more frequent while organic are rare and regress within 1.5-2 years. Complete cure of the patients should therefore be 1.5-2 years after discharge from the hospital.
The problem of pain has a major medico-social significance and necessitates detailed investigation both from the position of etiology and pathogenesis and new therapy methods. Among many methods of pain control drug-induced anesthesia is of great importance. The multiplicity of pain requires optimal use of analgetics and their combination with other agents strictly in coordination with individual needs of the patient. Special anesthesia systems are to be designed for this purpose.
Explore the source record for details and available documents.
To examine whether the cells of immune system express calcium channel-forming proteins, we studied the binding of calcium channel ligands, known to detect certain types of the above channels in excitable tissues, to murine splenic and human peripheral blood mononuclear cells. Specific (i.e., displaceable by excess cold ligand) binding of the 3H-labelled dihydropyridine drugs PN200-110 and nitrendipine, was not detected in these cells. Specific binding of a phenylalkylamine drug, [3H]verapamil, was detected, but cannot be attributed to the existence of certain specialized receptors, since multiple [3H]verapamil binding sites (about 10(6) per cell) appeared to be occupied. [3H]Verapamil binding to murine splenic mononuclear cells was inhibited following exposure to either the polyclonal T-cell activator, concanavalin A, or a cell-permeable analogue of the second messenger, cyclic AMP, suggesting that processes of lymphocyte activation and/or intracellular signalling may down-modulate at least some of calcium channel ligand binding sites.
A study is presented of 132 patients with hemorrhagic meningoencephalitis of viral, bacterial and viral-bacterial origin. Before admission to the clinic meningoencephalitis was diagnosed in 46.2% of patients. The cause of hypodiagnosis was underestimation of the clinical manifestations of the disease and anamnesis findings at the prehospital period. In 15.9% of patients the disease began with psychotic disorders. Lethality was 23.48%.
The authors studied the indices of general hemodynamics in 53 patients with initial manifestations of cerebro-circulatory insufficiency of young and middle age. Young patients suffering of cerebral atherosclerosis and vegetative-vascular dystonia showed a hyperkinetic type of hemodynamics while the middle-aged with atherosclerosis showed the hypokinetic type evidencing abnormal function of autoregulatory mechanisms.
A total of 94 cases were analyzed. Transient cerebral circulatory disorders in a majority of the patients with cardiac defects were caused by intraoperative factors. Clarification of these factors and the study of clinical course of the disorders made it possible to diagnose them timely and begin the differentiated treatment.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.
Explore the source record for details and available documents.